Hongyue Technology (Huzhou) Co., Ltd.

Main study objectives: To study the pharmacokinetics of the test preparation ropinirole hydrochloride tablets (specification: 0.25 mg, licensee: Hongyue Technology (Huzhou) Co., Ltd.) and the reference preparation ropinirole hydrochloride tablets (trade name: Requip®, specification: 0.25 mg, licensee: Graphos. Smiscline Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations. Secondary study objectives: To evaluate the safety of the test preparation (T) ropinirole hydrochloride tablets and the reference preparation (R) ropinirole hydrochloride tablets (Requip®) after a single oral administration in healthy subjects after fasting and feeding.

Main study objectives To study the pharmacokinetics of the test preparation bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine), produced by Ningbo Dahongying Pharmaceutical Co., Ltd. and provided by Hongyue Technology (Huzhou) Co., Ltd.) and the reference preparation bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine), licensed by Merck Kft) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations. Secondary study objectives To evaluate the safety of the test preparation (T) bisoprolol amlodipine tablets and the reference preparation (R) bisoprolol amlodipine tablets after a single oral administration in healthy subjects after a fasting and fed state.

Primary objective: To study the pharmacokinetics of the test preparation Eltrombopag Ethanolamine Tablets (Specification: 25 mg, Chongqing Saiwei Pharmaceutical Co., Ltd.) and the reference preparation Eltrombopag Ethanolamine Tablets (Revolan®, Specification: 25 mg, produced by Glaxo Operations UK Limited) in healthy adult subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary objective: To study the safety of the test preparation Eltrombopag Ethanolamine Tablets and the reference preparation Eltrombopag Ethanolamine Tablets (Revolan®) in healthy adult subjects after a single oral administration in the fed state.